Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study

Journal of Clinical Oncology

Volumn 13, Issue 12, 1995, Pages 2961-2967

  Francis, Prudence ^b   Rowinsky, Eric ^b   Schneider, Jeffrey ^b   Hakes, Thomas ^b   Hoskins, William ^b   Markman, Maurie ^b  

^a GOG Administrative Office   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAXIMUM ALLOWABLE CONCENTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0028862180     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.12.2961     Document Type: Article

References (15)

1. Markman M: Intraperitoneal chemotherapy. Semin Oncol 18:248-254, 1991
2. Wani MC, Taylor HL, Wall ME, et al: Plant antitumor agents VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from taxus brevifolia. J Am Chem Soc 893:2325-2327, 1971
3. Schiff PB, Fant J, Auster LA, et al: Effects of Taxol on cell growth and in vitro microtubule assembly. J Supramolec Struct 8:328, 1978 (suppl 2, abstr 822)
4. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 22:665-667, 1979
5. McGuire WP, Rowinsky EK, Rosenheim NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial ovarian neoplasms. Ann Intern Med 111:273-279, 1989
6. Thigpen T, Blessing J, Ball H, et al: Phase II trial of Taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 9:156, 1990 (abstr 604)
7. Einzig A, Wiernik P, Sasloff J, et al: Phase II study and long term follow up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
8. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
9. Sarosy G, Kohn E, Link C, et al: Taxol dose intensification in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 11:226, 1992 (abstr 716)
10. Markman M, Rowinsky E, Hakes T, et al: Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group study. J Clin Oncol 10:1485-1491, 1992
11. Rowinsky EK. Donehower RC, Jones RJ, et al: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48:4093-4100, 1988
12. Longnecker SM, Donehower RC, Cates AE, et al: High performance liquid chromatographic assay for Taxol (NSC 125973) in human plasma and urine pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1986
13. Monsarrat B, Mariel E, Crois S, et al: Taxol metabolism. Isolation and identification of three major metabolites in rat bile. Drug Metab Dispos 18:895-901, 1990
14. Rowinsky EK, Donehower RC: The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 20:16-25, 1993 (suppl 3)
15. Rowinsky EK, Donehower RC, Tucker RW: Microtubule changes and cytotoxicity produced by Taxol in human ovarian cancer cell lines. Proc Am Assoc Cancer Res 28:423, 1987 (abstr 1676)